Cite
HARVARD Citation
Necchi, A. et al. (2018). First‐line therapy with dacomitinib, an orally available pan‐HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open‐label, single‐arm, single‐centre, phase 2 study. BJU international. pp. 348-356. [Online].